The modulation of 5-HT3 receptor responses by anticancer drug
Project/Area Number |
23791895
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Otorhinolaryngology
|
Research Institution | Osaka University |
Principal Investigator |
NAKAMURA Yukiko 大阪大学, 医学(系)研究科(研究院), 助教 (90548083)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 頭頸部外科学 / セロトニン / 受容体 / セロトニン3受容体 / 抗癌剤 / 嘔吐 |
Research Abstract |
It has been shown that anti-cancer drug induces secretion of serotonin (5-HT) from small intestine which activates serotonin type 3 (5-HT3) receptor to cause nausea and vomiting. In general, antagonist for 5-HT3 receptor is used as anti-emetics during chemotherapy. However, we found that anti-cancer drug irinotecanitself inhibits 5-HT -gated current through the homomeric 5-HT3 receptor in aconcentration-dependent manner. Our findings suggest that irinotecan itself could have anti-emetic activities through inhibition of the 5-HT3 receptor.
|
Report
(3 results)
Research Products
(16 results)